Pemetrexed News and Research

RSS

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

Extended pleurectomy decortication plus chemotherapy associated with worse outcomes for mesothelioma patients

Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to platinum and pemetrexed chemotherapy alone, according to research presented today the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

Study points to a new, effective treatment option for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

8 Nov 2021

Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria, according to research presented today in OA13: Topics in Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer.

12 Sep 2021

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival in patients with nonsquamous non-small cell lung cancer with untreated and asymptomatic brain metastases.

12 Sep 2021

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand.

17 Mar 2021

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

Novel immunotherapy-plus-chemotherapy combo for pleural mesothelioma shows promise

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.

11 Jun 2020

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma.

20 May 2020

NCCN ORP plans to support phase II randomized trial for lung cancer patients

The National Comprehensive Cancer Network Oncology Research Program today announced plans to support a phase II randomized trial for lung cancer patients.

28 Oct 2019

New combination therapy found to be well tolerated in patients with aggressive brain tumor

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients.

30 Mar 2019

Patients with stage IV disease now living a median 6.8 years after ALK+ NSCLC diagnosis

According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chance of being alive 5 years later. For patients with stage IV disease, describing cancer that has spread to distant sites beyond the original tumor, that statistic drops to 2 percent.

2 Jan 2019

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Pemetrexed News and Research

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

Extended pleurectomy decortication plus chemotherapy associated with worse outcomes for mesothelioma patients

Study points to a new, effective treatment option for patients with mesothelioma

Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Novel immunotherapy-plus-chemotherapy combo for pleural mesothelioma shows promise

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

NCCN ORP plans to support phase II randomized trial for lung cancer patients

New combination therapy found to be well tolerated in patients with aggressive brain tumor

Patients with stage IV disease now living a median 6.8 years after ALK+ NSCLC diagnosis

Toxic effects of drugs in the lungs 'more widespread than thought'

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News